XELOX Renal Dose Adjustment
For patients with severe renal impairment (CrCl <30 mL/min), reduce oxaliplatin to 65 mg/m² and capecitabine is contraindicated; for moderate impairment (CrCl 30-49 mL/min), reduce capecitabine to 75% of standard dose (750 mg/m² twice daily) with standard oxaliplatin dosing; no dose adjustment is needed for mild impairment (CrCl 50-79 mL/min), though close monitoring is warranted.
Oxaliplatin Dose Adjustment
The FDA label provides clear guidance for oxaliplatin dosing based on renal function 1:
- CrCl ≥50 mL/min (mild impairment): No dose reduction required - use standard 85 mg/m² (adjuvant) or 85 mg/m² (advanced disease)
- CrCl 30-49 mL/min (moderate impairment): No dose reduction required per FDA label
- CrCl <30 mL/min (severe impairment): Reduce to 65 mg/m²
This recommendation is supported by pharmacokinetic data showing increased AUC of unbound platinum in severe renal impairment 1. A dose-escalation study demonstrated that oxaliplatin at 130 mg/m² was well tolerated in patients with CrCl >20 mL/min, supporting the lack of dose reduction in mild-moderate dysfunction 2.
Capecitabine Dose Adjustment
The NCCN guidelines note that "patients with diminished creatinine clearance may require dose modification of capecitabine" 3. Based on pharmacokinetic and safety data 4:
- CrCl ≥50 mL/min: Standard dosing (1000 mg/m² twice daily for 14 days, every 21 days)
- CrCl 30-49 mL/min (moderate impairment): Reduce to 75% of standard dose = 750 mg/m² twice daily
- CrCl <30 mL/min (severe impairment): Capecitabine is contraindicated - all patients with severe impairment experienced grade 3-4 adverse events in pharmacokinetic studies 4
The rationale: Renal impairment increases systemic exposure to 5'-DFUR (the penultimate metabolite) by 23% for each 50% reduction in CrCl, and this exposure strongly correlates with grade 3-4 toxicity 4.
Critical Clinical Considerations
Calculate CrCl using Cockcroft-Gault equation - this is the method validated in the pharmacokinetic studies and specified in FDA labeling 1.
Borderline renal function (CrCl 50-80 mL/min) requires vigilance: Even with "normal" renal function by traditional cutoffs, patients in this range experience higher rates of dose modifications and toxicity 5, 6. In elderly patients (≥65 years) with CrCl 50-80 mL/min receiving standard-dose XELOX, 42.3% experienced grade 3 adverse events and 21.1% discontinued within 4 cycles 5.
Standardized creatinine measurements matter: Patients with "pseudo-normal" renal function (CrCl >50 mL/min by standardized creatinine but ≤50 mL/min when adjusted) have significantly higher rates of grade ≥2 thrombocytopenia 7. If your laboratory uses enzymatic creatinine measurement, consider adding 0.2 mg/dL to the value when calculating CrCl for capecitabine dosing decisions.
Monitoring Strategy
For patients with CrCl 50-80 mL/min on standard dosing:
- Monitor CBC and metabolic panel before each cycle
- Assess for hand-foot syndrome, diarrhea, and mucositis weekly during the first 2 cycles
- Consider empiric dose reduction to capecitabine 850 mg/m² twice daily in elderly patients (≥65 years) with CrCl 50-65 mL/min
Common pitfall: Using estimated GFR (eGFR) instead of CrCl - the dosing recommendations are based on Cockcroft-Gault calculated CrCl, not MDRD or CKD-EPI eGFR 1, 4.